| Dr Joe C Beshears, MD | |
|
205 Marengo St, Florence, AL 35630-6033 | |
| (256) 768-9509 | |
| (256) 768-9715 |
| Full Name | Dr Joe C Beshears |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 205 Marengo St, Florence, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104141761 | NPI | - | NPPES |
| IP1161 | Other | KY | INSTITUTIONAL - UNIVERSITY OF KENTUCKY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 32750 (Alabama) | Primary |
| 207R00000X | Internal Medicine | IP1161 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Alabama Medical Center | Florence, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ecm Health Group Llc | 9436395225 | 87 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
| Entity Name | Marshall Medical Center North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740439587 PECOS PAC ID: 8022176346 Enrollment ID: O20081015000251 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
| Entity Name | Physynergy Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134465560 PECOS PAC ID: 6204081292 Enrollment ID: O20130222000456 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
| Entity Name | Ecm Health Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346588852 PECOS PAC ID: 9436395225 Enrollment ID: O20130424000304 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
| Entity Name | Madison Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538540729 PECOS PAC ID: 9335417385 Enrollment ID: O20170614002690 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joe C Beshears, MD P.o. Box 10005, Florence, AL 35631-2005 Ph: (256) 768-9509 | Dr Joe C Beshears, MD 205 Marengo St, Florence, AL 35630-6033 Ph: (256) 768-9509 |
News Archive
Key factors have been identified that help determine the vulnerability of public-supply wells to contamination. A new USGS report describes these factors, providing insight into which contaminants in an aquifer might reach a well and when, how and at what concentration they might arrive.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.
Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
› Verified 9 days ago
Dr. Edsel P Holden Ii, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3905 Peach St, Florence, AL 35630 Phone: 256-767-5864 Fax: 256-263-4512 | |
Khushdeep Singh Chahal, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 205 Marengo Street, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Dr. Heather Brody, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 180 Cox Creek Pkwy S Ste B, Florence, AL 35630 Phone: 256-760-0422 Fax: 256-284-6065 | |
John D Morris, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 205 Marengo Street, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Danny Wayne Mcfall, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 409 North Cedar Street, Florence, AL 35630 Phone: 256-766-3062 Fax: 256-767-1804 | |
Gabriel Hamilton Hester, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 205 Marengo St, Florence, AL 35630 Phone: 256-768-9509 Fax: 256-768-9715 | |
Dr. Rajesh Boorgu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 422 E Dr Hicks Blvd, Florence, AL 35630 Phone: 256-766-1401 Fax: 256-766-1402 |